Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology Cept, Warsaw, Poland.
Doctoral School of Medical University of Warsaw, Poland.
Platelets. 2022 Oct 3;33(7):1052-1064. doi: 10.1080/09537104.2022.2042233. Epub 2022 Mar 14.
MicroRNAs (miRNAs) are small, non-coding RNAs, able to regulate cellular functions by induction of mRNA degradation and post-transcriptional repression of gene expression. Platelets are the major source of circulating miRNAs, with significant regulatory potential on cardiovascular pathophysiology and other diseases. MiRNAs have been shown to modify the expression of platelet proteins, which influence the platelets reactivity. Circulating miRNAs can be determined from plasma, serum, or whole blood, and they can be used as diagnostic and prognostic biomarkers as well as therapeutic targets including cardiovascular diseases (CVDs). Herein, we present original results from bioinformatic analyses, which identified top 22 platelet-related miRNAs including hsa-miR-320a, hsa-miR-16-5p, hsa-miR-106a-5p, hsa-miR-320b, hsa-miR-15a-5p, hsa-miR-15b-5p, hsa-miR-195-5p, hsa-miR-92a-3p as widely involved in platelet reactivity and associated diseases, including CVDs, Alzheimer's and cerebrovascular diseases, cancer and hypertension. Analysis focused on the identification of the highly regulatory targets shared between those miRNAs identified 43 of them. Best ranked genes associated with overall platelet activity and most susceptible for noncoding regulation were PTEN, PIK3R1, CREB1, APP, and MAPK1. Top targets also strongly associated with CVDs were VEGFA, IGF1, ESR1, BDNF, and PPARG. Top targets associated with other platelet-related diseases including cancer identified in our study were TP53, KRAS, and CCND1. The most affected pathways by top miRNAs and top targets included diseases of signal transduction by Growth Factor Receptors (GDFRs) and second messengers, platelet activation, signaling, and aggregation, signaling by VEGF, MAPK family signaling cascades, and signaling by Interleukins. Terms specific only for platelet-related miRNAs included coronary artery disease, platelet degranulation, and neutrophil degranulation, while for the top platelet-related genes it was Estrogen Signaling Receptor (ESR) mediated signaling, extra-nuclear estrogen signaling, and endometriosis. Our results show the novel features of platelet physiology and may provide a basis for further clinical studies focused on platelet reactivity. They also show in which aspects miRNAs can be promising biomarkers of platelet-related pathological processes.
微小 RNA(miRNA)是一种小型非编码 RNA,能够通过诱导 mRNA 降解和基因表达的转录后抑制来调节细胞功能。血小板是循环 miRNA 的主要来源,对心血管病理生理学和其他疾病具有重要的调节潜能。已经证明 miRNA 可以改变血小板蛋白的表达,从而影响血小板的反应性。循环 miRNA 可以从血浆、血清或全血中确定,它们可用作诊断和预后生物标志物,以及包括心血管疾病(CVD)在内的治疗靶点。在此,我们展示了生物信息学分析的原始结果,这些结果确定了包括 hsa-miR-320a、hsa-miR-16-5p、hsa-miR-106a-5p、hsa-miR-320b、hsa-miR-15a-5p、hsa-miR-15b-5p、hsa-miR-195-5p、hsa-miR-92a-3p 在内的 22 种血小板相关 miRNA,这些 miRNA 广泛参与血小板反应性和相关疾病,包括 CVD、阿尔茨海默病和脑血管疾病、癌症和高血压。分析集中在鉴定这些 miRNA 之间共享的高度调节靶标上,确定了其中 43 个。与整体血小板活性最相关且最易受非编码调节的最佳排名基因是 PTEN、PIK3R1、CREB1、APP 和 MAPK1。与 CVD 强烈相关的顶级靶标还包括 VEGFA、IGF1、ESR1、BDNF 和 PPARG。在我们的研究中,与其他血小板相关疾病(包括癌症)相关的顶级靶标还包括 TP53、KRAS 和 CCND1。受顶级 miRNA 和顶级靶标影响最大的途径包括生长因子受体(GDFRs)和第二信使的信号转导、血小板激活、信号转导和聚集、VEGF 信号转导、MAPK 家族信号级联和白细胞介素信号转导。仅与血小板相关 miRNA 相关的术语包括冠状动脉疾病、血小板脱颗粒和中性粒细胞脱颗粒,而与顶级血小板相关基因相关的术语是雌激素信号受体(ESR)介导的信号转导、核外雌激素信号转导和子宫内膜异位症。我们的结果显示了血小板生理学的新特征,可为进一步关注血小板反应性的临床研究提供基础。它们还表明了 miRNA 可以在哪些方面成为血小板相关病理过程有前途的生物标志物。